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Background: COPD Assessment in Primary Care To Identify Undiagnosed Respiratory Dis-
ease and Exacerbation Risk (CAPTURE™) uses five questions and peak expiratory flow (PEF) 
thresholds (males #350 L/min; females #250 L/min) to identify patients with a forced expiratory 
volume in 1 second (FEV
1
)/forced vital capacity (FVC) ,0.70 and FEV
1
 ,60% predicted or 
exacerbation risk requiring further evaluation for COPD. This study tested CAPTURE’s ability 
to identify symptomatic patients with mild-to-moderate COPD (FEV
1
 60%–80% predicted) who 
may also benefit from diagnosis and treatment.
Methods: Data from the CAPTURE development study were used to test its sensitivity (SN) 
and specificity (SP) differentiating mild-to-moderate COPD (n=73) from no COPD (n=87). 
SN and SP for differentiating all COPD cases (mild to severe; n=259) from those without COPD 
(n=87) were also estimated. The modified Medical Research Council (mMRC) dyspnea scale and 
COPD Assessment Test (CAT™) were used to evaluate symptoms and health status. Clinical 
Trial Registration: NCT01880177, https://ClinicalTrials.gov/ct2/show/NCT01880177?term=N
CT01880177&rank=1.
Results: Mean age (+SD): 61 (+10.5) years; 41% male. COPD: FEV
1
/FVC=0.60 (+0.1), FEV
1
% 
predicted=74% (+12.4). SN and SP for differentiating mild-to-moderate and non-COPD patients 
(n=160): Questionnaire: 83.6%, 67.8%; PEF (#450 L/min; #350 L/min): 83.6%, 66.7%; CAPTURE 
(Questionnaire+PEF): 71.2%, 83.9%. COPD patients whose CAPTURE results suggested that diag-
nostic evaluation was warranted (n=52) were more likely to be symptomatic than patients whose 
results did not (n=21) (mMRC .2: 37% vs 5%, p,0.01; CAT.10: 86% vs 57%, p,0.01). 
CAPTURE differentiated COPD from no COPD (n=346): SN: 88.0%, SP: 83.9%.
Conclusion: CAPTURE (450/350) may be useful for identifying symptomatic patients with 
mild-to-moderate airflow obstruction in need of diagnostic evaluation for COPD. 
Keywords: COPD, case-finding, undiagnosed COPD, screening tool, peak expiratory flow
Introduction
COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease 
and Exacerbation Risk (CAPTURE™) was developed to identify people with severe, 
high-risk undiagnosed COPD, defined as a forced expiratory volume in 1 second 
(FEV
1
) ,60% predicted or exacerbation risk, in primary care settings.1,2 This case-
finding method uses five simple patient-completed questions and the selective use of 
peak expiratory flow (PEF) to uncover individuals most likely to benefit from diagnosis 
and treatment.1–8 The intent is to be as efficient as possible, using PEF selectively based 
on questionnaire score and reserving spirometry referrals to the subset of patients 
whose results warrant further diagnostic evaluation.1,3,4
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Although this case-finding method was developed to iden-
tify undiagnosed patients with an FEV
1
% predicted ,60% 
or at risk of exacerbation, uncovering symptomatic patients 
with FEV
1
% predicted .60% who might also benefit from 
treatment could be advantageous. This study explored the 
extent to which CAPTURE identifies these patients.
In its initial testing, CAPTURE was able to differentiate 
cases of COPD (FEV
1
% predicted ,60% or exacerbation 
risk) from controls without COPD with a sensitivity (SN) of 
89.7% and specificity (SP) of 93.1% (n=273). When subjects 
with milder COPD (FEV
1
% predicted $60% and no/low 
exacerbation risk) were included in the control group, testing 
the ability of CAPTURE to differentiate the more severe, 
high-risk patients from all others, SN was 89.7% and SP was 
78.1% (n=346).1 The change in SP indicated that CAPTURE 
was classifying some patients with milder airflow obstruction 
as cases, a finding interpreted as error because the intent was 
to find the more severe, high-risk patients.1 Upon further 
reflection, we questioned whether these “misclassified” cases 
may represent an additional group of patients who might 
also benefit from diagnosis and treatment. Although screen-
ing of asymptomatic individuals for undiagnosed COPD is 
not recommended,9 identifying symptomatic patients with 
mild-to-moderate airflow limitation could be advantageous, 
with treated individuals potentially realizing symptomatic, 
activity tolerance, and health-status benefits.10–14
Methods
Design
This was a secondary analysis of data from the prospective, 
cross-sectional, multisite, case–control study used to 
develop CAPTURE.1,15 Specific methods and procedures 
for the larger study are presented elsewhere.1 The study 
was approved by a central institutional review board (IRB) 
(Schulman Associates) and IRBs at each study site (Colum-
bia University, National Jewish Health, Olmsted Medical 
Center, University of Kentucky, University of Michigan, 
and University of Nebraska Medical Center). Each patient 
provided written informed consent before initiating study 
procedures. Briefly, for questionnaire development, a pool 
of 44 candidate questions and criterion measures were com-
pleted by patients identified as cases (n=186; FEV
1
 ,60% or 
$1 exacerbation the previous 12 months) or controls (n=160; 
including patients with COPD and FEV
1
 $60% predicted 
and no exacerbations the prior 12 months [n=73] and those 
without COPD [n=87]).1 COPD was defined by physician 
diagnosis with prescribed pharmacologic maintenance ther-
apy and FEV
1
/FVC ,0.70. COPD patients with an FEV
1
% 
predicted of 60%–80% were included in the control group to 
optimize the selection of items most sensitive to more severe, 
high-risk COPD during random forests analyses. The preci-
sion of the questionnaire alone, PEF alone, and CAPTURE 
(Questionnaire+PEF) for differentiating cases (n=186) from 
non-COPD controls (n=87) was also tested.1
To address the purpose of the current study, analyses were 
performed on data from the original control group (n=160), 
with cases defined by a diagnosis of COPD, FEV
1
 $60% pre-
dicted, and no exacerbation the prior 12 months (n=73) and 
those with no COPD serving as controls (n=87). The entire 
dataset (n=346) was used to evaluate CAPTURE across the 
full range of COPD (n=259), with patients without COPD 
(n=87) serving as controls.
Measures
The CaPTUre Questionnaire
The CAPTURE Questionnaire (Figure 1) comprises five ques-
tions assessing the presence/absence of symptoms (breathing 
problems and tiring easily), risk exposures, and recent history 
of acute respiratory illnesses. Responses are summed to yield 
a score ranging from 0 (no to all 5 questions) to 6 (yes to all 
questions and .2 respiratory events during the past year). 
Scores $2 indicate that further diagnostic assessment for 
COPD is warranted. In its initial testing, scores $2 showed 
an SN of 95.7% and an SP of 44.4% for differentiating 
COPD cases (FEV
1
% predicted ,60% or exacerbation 
risk) from controls (mild/moderate no risk COPD or no 
COPD) and an SN of 95.7% and an SP of 67.8% for dif-
ferentiating cases from those without COPD.1 
PeF
PEF is used to increase the precision of case identification. In 
the development/validation study, research staff supervised 
PEF administration (Vitalograph® AsmaPlan® mechanical PEF 
meter; Vitalograph Ltd, Buckingham, UK) during the clinic 
visit; each subject performed three maneuvers with the highest 
value (L/min) used for analyses. Sex-specific thresholds were 
identified to facilitate rapid interpretation in clinical practice 
prior to referral for diagnostic spirometry: males ,350 L per 
minute (L/min) and females ,250 L/min.1
CaPTUre (Questionnaire+PeF)
Questionnaire scores are used to select the best subset of 
patients for PEF testing. Those scoring 0 or 1 on the question-
naire are unlikely to have COPD and can proceed with the 
remainder of their clinic visit. Those scoring 5 or 6 (yes to 
all items and $1 respiratory events the past year) may have 
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undiagnosed disease and can be referred directly to spirom-
etry. Patients scoring 2–4 are clinically equivocal, with PEF 
values relative to thresholds used to determine next steps 
(spirometry and no spirometry). In the development study, 
this two-step process, using the 350/250 L/min thresholds, 
improved SN and SP over the questionnaire alone for dif-
ferentiating cases and controls (89.7% and 78.1%) and cases 
and no-COPD controls (89.7% and 93.1%), with the added 
advantage of eliminating the need for PEF assessments in 
all patients.1
Modified British Medical Research Council dyspnea 
scale (mMrC) and COPD assessment Test (CaT™)
The mMRC16,17 and CAT™18,19 were used to assess patient-
reported dyspnea and COPD-related health status, respec-
tively. The mMRC is a 5-point (0–4) scale with higher ratings 
reflecting more severe breathlessness. CAT scores range from 
0 to 40 with higher scores indicating poorer COPD health 
status. Patient-level scores ,10 are interpreted as low-impact 
COPD, with continued health maintenance interventions 
advised, including smoking cessation, vaccination, and exer-
cise. Scores 10–20 are considered moderate-impact COPD 
with potential for improvement with treatment, for example, 
maintenance therapies, reduction in aggravating factors, 
exacerbation prevention, and/or rehabilitation.20 mMRC 
.2 and CAT scores .10 are used to categorize patients as 
“more symptomatic” under the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines.21
spirometry
Pre-bronchodilator spirometry (FEV
1
, FEV
1
% predicted, 
and FEV
1
/forced vital capacity [FVC]) was performed if 
spirometry results from the past 5 years were not available. 
FEV
1
/FVC ,0.70 and FEV
1
 ,80% predicted were con-
sidered diagnostic of COPD. All COPD cases met COPD 
Foundation Guide spirometry grade 1 requirements (FEV
1
 
$60%; ,80% predicted).7
analyses
Group differences in sample characteristics were tested 
using parametric (normally distributed continuous variables) 
and nonparametric (categorical and non-normal continuous 
variables) statistics. PEF values were also compared using 
analysis of variance, with factors for group, sex, smoking, 
age, and group-by-sex interaction.
The precision of the questionnaire, PEF (350/250), and 
CAPTURE (Questionnaire+PEF [350/250]) for differenti-
ating patients with and without COPD in this sample was 
estimated using SN, SP, overall misclassification error esti-
mates, receiver operator characteristic curves, and area under 
the curve.
The SN, SP, and error for PEF alone were examined in 
25 mL increments stratified by sex to determine if higher thresh-
olds more accurately differentiated these cases of COPD from 
those without COPD, with consideration given to threshold 
values that would be easy to recall and apply in clinical settings. 
Figure 1 The CaPTUre™ (COPD assessment in primary care to identify undiagnosed respiratory disease and exacerbation risk) questionnaire.
Notes: scoring: no =0; Yes =1; Item 5: 0, 1, 2. scores are summed. © Cornell University, University of Kentucky research Foundation, and evidera, Inc. all rights reserved.
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The best thresholds were then tested with the questionnaire 
to determine if new thresholds for males and females would 
enhance the precision of CAPTURE in this population.
The extent to which CAPTURE was identifying COPD 
patients with dyspnea (mMRC levels .2) and/or poor health 
status (CAT scores .10) was tested using Chi-square (χ2) 
or Fisher’s exact (cell n ,5) statistics and performed using 
the 350/250 and the higher PEF thresholds.
Finally, SN, SP, and error for differentiating the full range 
of COPD (n=259) from no COPD (n=87) were assessed for 
the questionnaire alone, PEF alone, and CAPTURE using 
the 350/250 and higher PEF thresholds.
Results
sample
Demographic and clinical characteristics of the analytical 
sample are shown in Tables 1 and 2. Subjects without COPD 
were younger and more likely to be female, employed, and 
have a higher educational level than the COPD group.
Of the 73 patients with milder COPD, 23 (31.5%) were 
GOLD airflow limitation category 1 (mild) and 50 (68.5%) 
were GOLD 2 (moderate).21 COPD patients had significantly 
poorer lung function, higher mMRC and CAT scores, and 
were more likely to have a smoking history and one or more 
comorbid conditions than those with no COPD. PEF rates 
were significantly lower in the COPD group, tested alone and 
controlling for age (p,0.001), sex (p,0.0001), and smoking 
status (p,0.01) (LS means [95% CI]: COPD [n=73]: 324.3 
[301.6; 346.9]; no COPD [n=87]: 403.1 [381.2, 425.1]; 
F=27.78; p,0.001).
CaPTUre performance
Performance properties of the questionnaire, PEF, and 
questionnaire+PEF for these milder COPD cases versus no 
COPD are shown in Table 3A and Figure 2A. To assist with 
interpretation, results for the more severe high-risk COPD 
cases (FEV
1
 ,60% or risk of exacerbation) versus no COPD 
controls from the original development study1 are provided 
Table 1 Demographic characteristics by groupa
Characteristic n=160 p-value
COPDb 
(n=73)
No COPDc 
(n=87)
age (years)
Mean (sD) 65.2 (9.1) 58.1 (10.5) ,0.0001
range 49–85 40–88
sex, n (%) male 40 (55) 26 (30) 0.0014
ethnic background, n (%)
not hispanic or latino 68 (99) 84 (99) 1.000
racial background, n (%)d
White 66 (90) 73 (84) 0.2250a
non-white 7 (10) 14 (16)
employment, n (%)
employed (full- or part-time) 15 (21) 55 (63) ,0.0001
not employed 58 (79) 32 (37)
retired 37 (51) 22 (25)
Disabled 18 (25) 3 (3)
Otherse 3 (4) 7 (8)
education status, n (%) 0.0006
high school or less 36 (49) 18 (21)
some college, vocational training 14 (19) 22 (25)
College degree or more 23 (32) 47 (54)
Notes: aenglish-speaking with informed consent and spirometry. bCOPD, FeV1 60%–
80% predicted, and no history of exacerbations .12 months. cno known diagnosis 
or treatment for COPD and FeV1/FVC $0.70. 
dSubject self-identified; American 
Indian or alaskan native (1,1), asian (0,1), Black or african american (11, 5), and 
others (2,0). eOthers: homemaker, unemployed, and not specified.
Abbreviation: FeV1, forced expiratory volume in 1 second.
Table 2 Clinical characteristics by groupa
Characteristic n=160 p-value
COPDb 
(n=73)
No COPDc 
(n=87)
smoking history, n (%) ,0.0001
never or ,100 cigarettes 2 (3) 51 (59)
Former 48 (66) 28 (32)
Current 23 (32) 8 (9)
spirometry
FeV1, median 2.0 2.6 ,0.0001
Mean (sD) 2.1 (0.6) 2.6 (0.7)
FeV1% predicted 70.0 93.0 ,0.0001
Mean (sD) 74.0 (12.4) 89.7 (14.6)
FeV1/FVC, mean (sD) 0.6 (0.1) 0.8 (0.1) ,0.0001
Peak flow (PEF) 316.1 
(102.86)
403.5 
(109.00)
,0.0001
mMrC dyspnea scale (0–4 scale)
Median 2 1 ,0.0001
Mode (n, %) 1 (34; 46) 0 (71; 82)
mMrC .2 20 (28) 5 (6)
CaT™ (0–40 scale)
Median 15.0 4.0 ,0.0001
Mean (sD) 15.6 (8.0) 5.5 (5.4)
CaT .10, n (%) 57 (78) 13 (15) ,0.0001
mMrC .2 or CaT .10, 
n (%)
57 (78) 15 (17) ,0.0001
mMrC .2 and CaT .10, 
n (%)
20 (28) 3 (3) ,0.0001
Comorbid conditions (any), 
n (%) yes
73 (100) 76 (87) 0.0010
self-report activity on most 
days, n (%)
0.0524
sit, lie down, walk around 
home
38 (52) 32 (37)
Very active or exercise 35 (48) 55 (63)
Notes: aenglish-speaking subjects with informed consent and spirometry. bCOPD, 
FeV1 60%–80% predicted, and no history of exacerbations .12 months. 
cno known 
diagnosis or treatment for COPD and FeV1/FVC $0.70.
Abbreviations: CaT, COPD assessment Test; FeV1, forced expiratory volume 
in 1 second; FVC, forced vital capacity; mMRC, modified Medical Research Council 
dyspnea scale; PEF, peak expiratory flow.
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in Table 3B and Figure 2B. Results for all COPD versus no 
COPD are shown in Table 3C and Figure 2C. SN analyses 
for smoking status are included in Tables S1–S3, with results 
suggesting that this was not a confounding factor.
Questionnaire alone
Most COPD patients (61/73; 83.6%) scored $2 on the ques-
tionnaire, the threshold for further evaluation of COPD. The 
questionnaire was less sensitive differentiating milder COPD 
from no COPD (83.6%, Table 3A), relative to its use detect-
ing more severe cases of COPD (95.7%, Table 3B). 
PeF alone
PEF (350/250 threshold) was less sensitive differentiating 
milder COPD patients from those without COPD (38.4%, 
Table 3A) relative to its performance with more severe 
cases of COPD (88.0%, Table 3B). Precision estimates for 
PEF at 25 L/min increments are shown in Table S4A and B. 
Increasing the threshold by 100 L/min (to 450/350 for males/
females) improved the SN of PEF from 38.4% to 83.6%, with 
some sacrifice in SP, from 90.8% to 66.7% (Table 3A). 
CaPTUre (Questionnaire+PeF)
As one might expect given its purpose and development 
methods, CAPTURE (PEF 350/250) had substantially lower SN 
for detecting patients with milder airflow obstruction (39.7%, 
Table 3A) compared to the detection of patients with more 
severe, high-risk COPD (89.7%, Table 3B). Using CAPTURE 
(PEF 450/350) improved the SN from 39.7% to 71.2%, with 
some sacrifice in SP, from 93.1% to 83.9% (Table 3A). 
Dyspnea and health status
Most of the milder COPD patients scoring $2 on the ques-
tionnaire reported either dyspnea (mMRC $2; n=50/60; 
83.3%) or health status impairment (CAT $10/60; n=54/60; 
88.5%). For patients with questionnaire scores ,2, most 
(9/12; 75%) had an mMRC ,2 (mMRC missing for one 
subject) or CAT ,10 (9/12, 75%).
COPD patients whose CAPTURE (PEF 350/250) indicated 
the need for further diagnostic evaluation (n=29) were more 
likely to report dyspnea (mMRC scores $2, p,0.05) than those 
who did not (n=44). There was no difference in health status 
(CAT $10) between the two groups (Table S5).
Table 3 Performance properties for questionnaire, PeF, and CaPTUre for differentiating COPD from no COPD
A
Milder COPDa (n=73) versus no COPDb (n=87)
Property Questionnaire PEFc CAPTuREd
Score .2 350/250 
threshold
450/350 
threshold
350/250 
threshold
450/350 
threshold
sensitivity (%) 83.6 38.4 83.6 39.7 71.2
Specificity (%) 67.8 90.8 66.7 93.1 83.9
error (%) 25.0 33.1 25.6 31.3 21.9
B
Severe, high-risk COPDa (n=186) versus no COPDb (n=87)1
Property Questionnaire PEFc CAPTuREd
Score .2 350/250 threshold 350/250 threshold
sensitivity (%) 95.7 88.0 89.7
Specificity (%) 67.8 90.8 93.1
error (%) 13.2 11.1 9.2
C
Full range of COPDa (n=259) versus no COPDb (n=87)
Property Questionnaire PEFc CAPTuREd
Score .2 350/250 
threshold
450/350 
threshold
350/250 
threshold
450/350 
threshold
sensitivity (%) 92.3 73.9 94.2 75.5 88.0
Specificity (%) 67.8 90.8 66.7 93.1 83.9
error (%) 13.9 21.8 12.8 20.1 13.0
Notes: (A) aCOPD, FeV1 60–80% predicted and no history of exacerbations .12 months; 
bno known diagnosis or treatment for COPD and FeV1/FVC $ 0.70; 
cPeak 
expiratory flow (PEF) rate, liters per minute (L/min), thresholds: males/females; dCaPTUre = Questionnaire + PeF. (B) aCOPD, FeV1 , 60% predicted or exacerbation risk; 
bno known diagnosis or treatment for COPD and FeV1/FVC $ 0.70; 
cPeak expiratory flow (PEF) rate, liters per minute (L/min), thresholds: males/females; dCaPTUre = 
Questionnaire + PeF. (C) aMedical diagnosis and treatment for COPD; FeV1/FVC , 0.70; 
bno known diagnosis or treatment for COPD and FeV1/FVC $ 0.70; 
cPeak 
expiratory flow (PEF) rate, liters per minute (L/min), thresholds: males/females (n=344); dCaPTUre = Questionnaire + PeF.
Abbreviations: CaPTUre, COPD assessment in Primary Care to Identify Undiagnosed respiratory Disease and exacerbation risk; FeV1, forced expiratory volume in 1 
second; FVC, forced vital capacity; PEF, peak expiratory flow.
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Using the higher PEF threshold, COPD patients whose 
CAPTURE (PEF 450/350) suggested further evaluation 
(n=52) were more likely to be symptomatic (mMRC $2 
and CAT $10, p,0.01) than patients whose scores sug-
gested that no further assessment was warranted (n=21) 
(Table S3).
Using CaPTUre to detect a full range 
of COPD, mild to severe
As expected, using CAPTURE (PEF 350/250) to differ-
entiate all patients with COPD from those without COPD 
alters the precision of the case-finding approach relative 
to its original purpose, reducing SN (89.7%–75.5%) and 
Figure 2 rOC and aUC by group.
Notes: (A) mildera (n=73) versus no COPDb (n=87); (B) severe, high-risk COPDc (n=186) versus no COPDd (n=87); (C) all COPDe (n=259) versus no COPDf (n=87). 
aCOPD, FeV1 60%–80% predicted and no history of exacerbations .12 months. 
bno known diagnosis or treatment for COPD and FeV1/FVC $0.70. 
cFeV1 ,60% or 
exacerbation risk. dno known diagnosis or treatment for COPD and FeV1/FVC $0.70.
1 eMedical diagnosis and treatment for COPD; FeV1/FVC ,0.70. 
fno known diagnosis 
or treatment for COPD and FeV1/FVC $0.70.
Abbreviations: aUC, area under the curve; CaPTUre™, COPD assessment in Primary Care to Identify Undiagnosed respiratory Disease and exacerbation risk; 
FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow; ROC, receiver operating characteristics.
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increasing error (9.2%–20.1%). Increasing the PEF threshold 
improves SN from 75.5% to 88.0% and reduces error 
(20.1%–13.0%), with some sacrifice in SP (declines from 
93.1% to 83.9%).
Discussion
CAPTURE was designed to help primary care health pro-
fessionals efficiently identify severe, high-risk undiagnosed 
cases of COPD in greatest need of diagnosis and treatment. 
Many patients with FEV
1
 .60% are symptomatic, however, 
and may also benefit from treatment.10,11,13,14 The results of 
the analyses presented here suggest that CAPTURE can 
identify these milder patients with reasonable SN and SP 
when PEF thresholds of 450/350 are used. Although more 
patients would be referred for diagnostic spirometric testing, 
including those without COPD, a substantial portion of those 
ultimately diagnosed with COPD are likely to have dyspnea 
or health status impairment that may be ameliorated with 
treatment. 
Given the performance properties of PEF in the current 
analyses and previous study, one might be tempted to use PEF 
thresholds alone to identify patients in need of spirometry. 
However, organizing PEF supplies and performing three 
coached maneuvers with all patients in primary care settings, 
in addition to other clinic visit assessments, could be chal-
lenging. Furthermore, results of PEF provide preliminary 
information on airflow obstruction only, with no insight into 
exposure, symptoms, or exacerbation risk prior to referral 
for diagnostic testing. CAPTURE was designed to balance 
efficiency and precision, with the carefully designed ques-
tionnaire used as an initial screen and PEF administered to 
a subset of patients to yield fewer false positives and reduce 
screening costs. The PEF thresholds enable efficient inter-
pretation, with empirically tested quick-recall values (male/
female, moderate to severe: 350/250; mild to moderate: 
450/350), although clinicians can also use the observed 
value and clinical judgment to determine the need for further 
assessment and testing.
Given the relatively high CAT scores in patients with 
questionnaire scores $2, one might also ask if the CAT could 
be used for case finding. The CAT was developed to facilitate 
communication between COPD patients and clinicians,18 
covering eight common manifestations of COPD and scores 
used to guide treatment. It was neither intended for use in 
patients without COPD nor as a screening tool. Following 
diagnosis, the CAT can be used to guide treatment and 
monitor outcomes.22
Several limitations of this study should be noted. First, this 
was an analysis of data from a subset of subjects participating 
in the CAPTURE development study, rather than a large pro-
spective, population-based case-finding study. Results should 
be considered exploratory. Second, the COPD and no COPD 
groups differed on several sample characteristics. Some of 
these differences typify COPD and were expected; however, 
differences in demographics (particularly age, sex, and educa-
tion) and smoking history could have affected the findings. 
Although there is no reason to believe that demographic dif-
ferences altered patient responses to study measures, this must 
be recognized as a limitation with further study warranted. SN 
analyses in former smokers suggested that results were robust 
to smoking history. Third, spirometry values were measured 
without bronchodilator administration with the standard FEV
1
/
FVC diagnostic threshold of ,0.70. Although other diagnos-
tic indicators were also used for group assignment (medical 
diagnosis and treatment), the 0.70 threshold can result in 
an overestimation of older subjects with airflow limitation. 
Once again, further research is needed. Fourth, although 
CAPTURE has been tested and performs well identifying 
more severe, high-risk cases of COPD in Spanish-speaking 
patients,2 sample size precluded testing its performance in 
milder symptomatic COPD. Finally, CAPTURE is a tool to 
identify patients requiring further evaluation for COPD; it 
was not intended to diagnose or evaluate treatment and may 
detect problems other than COPD that warrant evaluation. It 
was also not intended for use as an outcome measure, with the 
CAT best suited to that purpose following diagnosis. 
Conclusion
Results of these analyses together with those from the origi-
nal validation study suggest that CAPTURE can be used to 
identify symptomatic patients likely to have airflow limitation 
and in need of further clinical evaluation for possible COPD. 
Based on the patient’s score on this questionnaire, clinicians 
can apply the 350/250 or 450/350 PEF thresholds as they 
determine the need for diagnostic spirometry. Further testing 
in a large prospective study of this case-finding approach 
and its effect on diagnosis, treatment, and patient-centered 
outcomes are warranted.
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Supplementary materials
sensitivity analyses: former smokers
Given the difference in smoking status between the two groups, 
SN analyses were performed, testing the performance of the 
questionnaire, PEF, and CAPTURE (Questionnaire+PEF 
[350/250 and 450/350]) for differentiating COPD and no 
COPD in former smokers only (n=56). Demographic and 
clinical characteristics of former smokers by group are shown 
in Tables S1 and S2. Results are presented in Table S3. 
SN, SP, and error were similar to values found in the entire 
sample (Table 3), suggesting that smoking history was not 
a confounding factor.
Peak expiratory flow (PEF)
Each subject performed three PEF maneuvers using a 
Vitalograph® AsmaPlan® mechanical PEF meter (Vitalograph 
Ltd, UK), with the highest value (L/min) used for analysis. 
Performance properties of PEF at varied thresholds in this 
sample stratified by sex are shown in Table S4.
Clinical characteristics of patients whose 
COPD assessment in Primary Care To 
Identify Undiagnosed respiratory Disease 
and exacerbation risk (CaPTUre™) 
suggests that further diagnostic 
evaluation is advised
CAPTURE was developed to identify patients in need of 
diagnostic evaluation for undiagnosed COPD and a forced 
expiratory volume in 1 second (FEV
1
) ,60% or exacerba-
tion risk. This study assessed the sensitivity (SN), specificity 
(SP), and error of this case-finding method for identifying 
patients with an FEV
1
 $60% predicted.
To assess whether the evaluation process was identifying 
symptomatic patients, dyspnea (modified Medical Research 
Council [mMRC] .2), or health status impairment (COPD 
Assessment Test [CAT™] .10) was examined. Table S5 shows 
the results of these analyses for the 350/250 and 450/350 PEF 
thresholds. In both cases, most of the patients who would be 
referred for further diagnostic evaluation reported impaired 
health status and a substantial portion reported dyspnea. 
Although more patients are referred for further testing when 
the higher PEF threshold (450/350) is used, those referred 
are more likely to report impaired health status or high levels 
of dyspnea compared to those whose scores suggested that 
no further testing was warranted. These results suggest that 
CAPTURE (PEF 450/350) may be useful for identifying cases 
of COPD with an FEV
1
 .60% predicted, many of whom meet 
GOLD guidelines for “more symptomatic” disease.
Table S1 Demographic characteristics of former smokers (n=76) by group
Characteristic Former smokers (N=76) p-value
COPDb (n=48) No COPDc (n=28)
age (years)
Mean (sD) 67.4 (7.9) 62.0 (11.1) 0.0284
range 51–85 40–88
sex, n (%) male 24 (50) 10 (36) 0.2270
ethnic background, n (%)
not hispanic or latino 46 (98) 28 (100) 1.000
racial background, n (%)d
White 44 (92) 25 (89)
non-white 4 (8) 3 (11) 0.7039
employment, n (%)
employed (full- or part-time) 10 (21) 10 (21) 0.0052
not employed/otherse 38 (79) 38 (79)
education status, n (%)
high school or less 22 (46) 22 (46) 0.0934
some college, vocational training 9 (19) 9 (19)
College degree or more 17 (35) 17 (35)
Notes: aenglish-speaking with informed consent and spirometry; bCOPD, FeV1 60%–80% predicted and no history of exacerbations .12 months; 
cno known diagnosis 
or treatment for COPD and FeV1/FVC $0.70; 
dSubject self-identified; non-white: American Indian or Alaskan Native (1, 1), Asian (0, 1), Black or African American (1, 2), 
others (1, 0). eOthers: homemaker, unemployed, and not specified.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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Table S3 Performance of the questionnaire, PeF, and CaPTUrec for differentiating COPDa (n=48) from no COPDb (n=28) in former 
smokers (n=76)
Property Questionnaire PEFc CAPTuREc (Questionnaire+PEF)
Score .2 350/250 threshold 450/350 threshold 350/250 threshold 450/350 threshold
sensitivity (%) 87.5 33.3 81.3 39.6 70.8
Specificity (%) 67.9 92.9 57.1 96.4 85.7
error (%) 19.7 44.7 27.6 39.5 23.7
Notes: aCOPD, FeV1 60%–80% predicted, and no history of exacerbations .12 months; 
bno known diagnosis or treatment for COPD and FeV1/FVC $0.70. 
cPeF rate (l/min), 
thresholds: males/females.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow.
Table S2 Clinical characteristics of former smokers (n=76) by group
Characteristic COPDb (n=48) No COPDc (n=28) p-value
spirometry, mean (sD)
FeV1, median 1.9 2.4 0.0023
Mean (sD) 2.0 (0.6) 2.5 (0.7)
FeV1% predicted, median 68.0 85.0 0.0020
Mean (sD) 73.5 (13.2) 85.0 (17.3)
FeV1/FVC 0.60 (0.06) 0.78 (0.06) ,0.0001
Peak flow (PEF) 320.9 (114.7) 396.3 (85.0) 0.0035
mMrC (0–4 scale)
Median 1 0 ,0.0001
Mode (n, %) 1 (24, 51) 0 (25, 89)
mMrC .2, n (%) 12 (26) 1 (4) 0.0243
CaT™
Median 15.0 5.0 ,0.0001
Mean (sD) 14.5 (6.6) 5.5 (4.7)
CaT .10, n (%) 38 (79) 5 (18) ,0.0001
mMrC .2 and CaT .10, n (%) 12 (26) 1 (4) 0.0243
mMrC .2 or CaT .10, n (%) 38 (79) 5 (18) ,0.0001
Comorbid conditions (any), n (%), yes 48 (100) 25 (89) 0.0466
self-report activity on most days, n (%)
sit, lie down, walk around home 26 (54) 10 (36) 0.1202
Very active or exercise 22 (46) 18 (64)
Notes: aenglish-speaking subjects with informed consent and spirometry; bCOPD, FeV1 60%–80% predicted and no history of exacerbations .12 months; 
cno known 
diagnosis or treatment for COPD and FeV1/FVC $0.70.
Abbreviations: CaT, COPD assessment Test; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; gOlD, global Initiative for Chronic Obstructive 
Lung Disease; mMRC, modified Medical Research Council dyspnea scale.
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Table S4 Performance properties of PeF thresholds for differentiating milder cases of COPDa from patients without COPDb by sex
Males (n=66)
Property PEF threshold (L/min)c
350 375 400 425 450d 475 500
sensitivity (%) 37.5 52.5 65.0 80.0 80.0 82.5 85.0
Specificity (%) 88.5 88.5 80.8 69.2 65.4 53.8 50.0
error (%) 42.4 33.3 28.8 24.2 25.8 28.8 28.8
Females (n=94)
Property PEFc threshold (L/min)
250 275 300 325 350d 375
sensitivity (%) 39.4 66.7 69.7 75.8 87.9 93.9
Specificity (%) 91.8 86.9 85.2 80.3 67.2 42.6
error (%) 26.6 20.2 20.2 21.3 25.5 39.4
Notes: aCOPD, FeV1 60%–80% predicted and no history of exacerbations .12 months. 
bno known diagnosis or treatment for COPD and FeV1/FVC $0.70. 
cPeF rate, l/min. 
dselected threshold.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow.
Table S5 Prevalence of dyspnea and health status by CaPTUre™ responsea in patients with COPDb (n=73)
Characteristic CAPTuRE (PEF 350/250)c
Diagnostic testing recommended
CAPTuRE (PEF 450/350)d
Diagnostic testing recommended
Yes, n=29 (40%) No, n=44 (60%) p-levele Yes, n=52 (70%) No, n=21 (30%) p-levele
mMrC .2, n (%) 12 (43) 8 (18) 0.0227 19 (37) 1 (5) 0.0042
CaT™ .10, n (%) 26 (90) 31 (70) 0.0817 45 (86) 12 (57) 0.0060
mMrC .2 and CaT .10, n (%) 12 (43) 8 (18) 0.0227 19 (37) 1 (5) 0.0042
Notes: aQuestionnaire+PeF results suggest that further diagnostic evaluation is warranted (yes/no). bCOPD, FeV1 60%–80% predicted, and no history of 
exacerbations .12 months. csensitivity=39.7%; specificity=93.1%; error=31.3% for milder patients versus no COPD. dsensitivity=71.2%; specificity=83.9%; error=21.9% for 
milder patients versus no COPD. eChi-square (χ2) or Fisher’s exact (cell n,5).
Abbreviations: CaT, COPD assessment Test; FeV1, forced expiratory volume in 1 second; mMRC, modified Medical Research Council dyspnea scale; PEF, peak 
expiratory flow.
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